Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.7047
+0.0337 (5.02%)
At close: Mar 26, 2026, 4:00 PM EDT
0.7000
-0.0047 (-0.67%)
After-hours: Mar 26, 2026, 4:10 PM EDT

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.291.50.58--
Revenue Growth (YoY)
-80.98%157.63%---
Gross Profit
0.291.50.58--
Selling, General & Admin
6.486.468.4320.9713.55
Research & Development
7.049.367.6392.4223.9
Total Operating Expenses
13.5215.8216.06113.3937.45
Operating Income
-13.23-14.32-15.47-113.39-37.45
Other Non-Operating Income (Expense)
0.08----
Total Non-Operating Income (Expense)
0.631.361.190.730.32
Pretax Income
-12.6-12.96-14.29-112.66-37.13
Net Income
-12.6-12.96-14.29-112.66-37.13
Net Income to Common
-12.6-12.96-14.29-112.66-37.13
Shares Outstanding (Basic)
76421
Shares Outstanding (Diluted)
76421
Shares Change (YoY)
18.67%52.31%118.31%55.69%0.72%
EPS (Basic)
-1.93-2.35-3.95-67.99-34.88
EPS (Diluted)
-1.93-2.35-3.95-67.99-34.88
Free Cash Flow
-12.89-13.57-12.27-25.01-37.69
Free Cash Flow Per Share
-1.97-2.46-3.39-15.09-35.41
Gross Margin
100.00%100.00%100.00%--
Operating Margin
-4631.12%-953.00%-2652.80%--
Profit Margin
-4409.16%-862.43%-2449.59%--
FCF Margin
-4512.35%-903.26%-2103.92%--
EBITDA
-13.21-14.3-15.46-113.21-37.17
EBITDA Margin
-4623.52%-951.52%-2651.59%--
EBIT
-13.23-14.32-15.47-113.39-37.45
EBIT Margin
-4631.12%-953.00%-2652.80%--
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q